XML 140 R123.htm IDEA: XBRL DOCUMENT v3.22.4
Note 19 - Stock-based Compensation - SARs Activity (Details) - Stock Appreciation Rights (SARs) [Member] - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Unvested (in shares) 515 593 641  
Outstanding, aggregate intrinsic value [1] $ 12,784 $ 16,854 $ 7,706 $ 10,250
Unvested, grant date weighted average cost (in dollars per share) $ 5.08 $ 4.44 $ 4.10  
Outstanding, weighted average remaining contractual life (Year) 5 years 1 month 6 days 5 years 1 month 6 days 5 years 1 month 6 days 5 years 3 months 18 days
Awarded (in shares) 34 30 48  
Granted, aggregate intrinsic value [1] $ 0 $ 0 $ 154  
Fair value at grant date (in dollars per share) $ 12.07 $ 9.69 $ 5.80  
Exercised (in shares) (114) (108) (96)  
Exercised, aggregate intrinsic value [1] $ 5,258 $ 4,239 $ 2,401  
Exercised weighted average fair value (in dollars per share) $ 3.63 $ 2.85 $ 2.88  
Forfeited (in shares) 0 0 0  
Unvested, grant date weighted average cost (in dollars per share) $ 6.02 $ 5.08 $ 4.44 $ 4.10
Forfeited (in shares) 0 0 0  
Unvested (in shares) 435 515 593 641
Outstanding, exercise price (in dollars per share) $ 35.60      
Outstanding, weighted average fair value (in dollars per share) $ 6.02 $ 5.08 $ 4.44 $ 4.10
Vested and exercisable (in shares) 307      
Vested and exercisable, aggregate intrinsic value [1] $ 10,181      
Vested and exercisable, weighted average fair value (in dollars per share) $ 5.06      
Vested and exercisable, weighted average remaining contractual life (Year) 4 years 2 months 12 days      
Unvested (in shares) 128      
Unvested, aggregate intrinsic value [1] $ 2,603      
Unvested, weighted average fair value (in dollars per share) $ 8.32      
Unvested, weighted average remaining contractual life (Year) 5 years 10 months 24 days      
Outstanding (in shares) 435 515 593 641
Outstanding, exercise price (in dollars per share) $ 35.60      
Vested in the current year (in shares) 54      
Vested in the current year, aggregate intrinsic value [1] $ 1,384      
Vested in the current year (in dollars per share) $ 6.50      
Minimum [Member]        
Outstanding, exercise price (in dollars per share) 15.24 $ 15.24 $ 14.02  
Granted, exercise price (in dollars per share) 47.17 47.17 37.30  
Exercised, exercise price (in dollars per share) 15.24 15.24 14.02  
Outstanding, exercise price (in dollars per share) 19.37 15.24 15.24 $ 14.02
Vested and exercisable, exercise price (in dollars per share) 19.37      
Unvested, exercise price (in dollars per share) 35.90      
Outstanding, exercise price (in dollars per share) 19.37 15.24 15.24 14.02
Vested in the current year, exercise price (in dollars per share) 15.24      
Maximum [Member]        
Outstanding, exercise price (in dollars per share) 50.71 40.00 40.00  
Granted, exercise price (in dollars per share) 74.92 50.71 37.30  
Exercised, exercise price (in dollars per share) 40.00 19.37 25.76  
Outstanding, exercise price (in dollars per share) 74.92 50.71 40.00 40.00
Vested and exercisable, exercise price (in dollars per share) 50.71      
Unvested, exercise price (in dollars per share) 74.92      
Outstanding, exercise price (in dollars per share) 74.92 50.71 40.00 40.00
Vested in the current year, exercise price (in dollars per share) 50.71      
Weighted Average [Member]        
Outstanding, exercise price (in dollars per share) 31.16 27.47 25.06  
Granted, exercise price (in dollars per share) 55.45 50.48 37.30  
Exercised, exercise price (in dollars per share) 21.55 16.40 16.33  
Outstanding, exercise price (in dollars per share) 35.60 31.16 27.47 25.06
Vested and exercisable, exercise price (in dollars per share) 31.81      
Unvested, exercise price (in dollars per share) 44.69      
Outstanding, exercise price (in dollars per share) 35.60 $ 31.16 $ 27.47 $ 25.06
Vested in the current year, exercise price (in dollars per share) $ 39.36      
[1] Aggregate intrinsic value for SARs is defined as the amount by which the current market price of the underlying stock exceeds the exercise or grant price.